Related Experiment Video

Updated: Nov 15, 2025

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography
03:47

Retinal and Choroidal Thickness Changes in Populations with Helicobacter pylori Infection by Swept-Source Optical Coherence Tomography

Published on: November 1, 2024

317

The Effect of Helicobacter pylori Eradication on Lipid Levels: A Meta-Analysis

Jun Watanabe1, Masato Hamasaki1, Kazuhiko Kotani1

  • 1Division of Community and Family Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-City, Tochigi 329-0498, Japan.

Journal of Clinical Medicine
|March 6, 2021
PubMed

Insights

H. pylori eradication significantly increases high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels. This study highlights the impact of eradicating H. pylori infection on lipid profiles and cardiovascular health.

Area of Science:

  • Cardiovascular Health
  • Infectious Diseases
  • Lipid Metabolism

Background:

  • H. pylori infection is linked to cardiovascular diseases, but the role of lipids in this association is not fully understood.
  • Understanding lipid level changes after H. pylori eradication is crucial for assessing cardiovascular risk.

Purpose of the Study:

  • To review and analyze the changes in circulating lipid levels following H. pylori eradication.
  • To synthesize findings from randomized controlled trials (RCTs) and non-RCTs on H. pylori eradication and lipid profiles.

Main Methods:

  • A systematic literature search was conducted on the PubMed database up to December 2020.
  • Meta-analyses (inverse variance-weighted, random-effects) were performed on data from 24 studies (4 RCTs, 20 non-RCTs) involving 5270 participants.

Main Results:

  • H. pylori eradication led to increased levels of high-density lipoprotein cholesterol (HDL-C) (MD 2.28 mg/dL) and triglycerides (TG) (MD 3.22 mg/dL).
  • Low-density lipoprotein-cholesterol (LDL-C) levels showed minimal change (MD -2.33 mg/dL).
  • Elevated HDL-C findings were robust in RCT-only analyses, unlike TG changes.

Conclusions:

  • H. pylori eradication positively impacts lipid profiles, specifically increasing HDL-C levels.
  • Further research is required to determine the clinical implications of these lipid changes on cardiovascular disease outcomes.

Keywords:
Helicobacter infectioncardiovascular diseasehigh-density lipoproteininflammationlipid metabolismtriglyceride

More Related Videos

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

602
Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology03:33

Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology

Published on: May 23, 2025

447

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
723
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
227
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
318
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
851
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
755